A part of Merck

MAB8702 | Anti-Dengue Virus Type II Antibody, clone 3H5-1

MAB8702
100 µg  
Recuperando preço...
O preço não pôde ser recuperado
Quantidade mínima necessária para ser múltipla de
Após finalização do pedido Mais informações
Você salvou ()
 
Solicitar preço
Disponibilidade limitadaDisponibilidade limitada
Em estoque 
Descontinuado
Quantidades limitadas disponíveis
Disponibilidade a ser confirmada
    Restante: será informado
      Restante: será informado
      Vai informar
      Contatar o serviço de atendimento ao cliente

      Ofertas especiais

       

      Contatar o serviço de atendimento ao cliente

      Click To Print This Page

      Panorama geral

      Replacement Information

      Ofertas especiais

      Tabela com principais espec.

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H HI, IF M Purified Monoclonal Antibody
      Description
      Catalogue NumberMAB8702
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Dengue Virus Type II Antibody, clone 3H5-1
      Background InformationDengue fever is an acute, mosquito-transmitted viral disease characterized by fever, headache, arthralgia (severe retro-orbital pain), myalgia, rash, nausea, and vomiting. Infections are caused by any of the four closely related, but antigenically distinct virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross-protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. Dengue is primarily an urban disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Although most dengue infections result in relatively mild illness, some can produce Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome, with children being particularly at risk. Although epidemic outbreaks have been reported since 1779, the incidence has been increasing, with global, multiple serotype pandemics intensifying within the last 15 years. There is no specific antiviral therapy for dengue, but for both classical dengue and dengue hemorrhagic fever, symptomatic and supportive measures are effective. Important risk factors for DHF include the strain and serotype of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.
      References
      Product Information
      FormatPurified
      Control
      • Dengue positive patient sample
      PresentationProtein G Purified immunoglobulin. Liquid in 0.02 M PB, 0.25 M NaCl, pH = 7.6 with 0.1% Na Azide as a preservative
      Applications
      ApplicationThis Anti-Dengue Virus Type II Antibody, clone 3H5-1 is validated for use in HI, IF for the detection of Dengue Virus Type II.
      Key Applications
      • Hemagglutination Inhibition
      • Immunofluorescence
      Application NotesRecommended for use in an immunofluorescent assay. Also suitable for use in hemagglutination-inhibition tests and plaque-reduction assays.

      IFA: 1:200-1:400.

      Dilute with buffer pH 7.5-8.0 to desired working volumes. For extensive dilution, protein containing or other stabilizing medium should be used.

      Final working dilutions must be determined by end user.
      Biological Information
      ImmunogenDengue type 2 antigen (New Guinea C).
      Clone3H5-1
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      HostMouse
      SpecificityReacts with the Dengue type 2 virus.
      IsotypeIgG1
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Purification MethodProtein G Purified
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain at 2°C to 8°C in undiluted aliquots for up to 12 months after date of receipt.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      MSDS

      Título

      Ficha de Segurança de Produtos (MSDS) 

      Certificados de análise

      TítuloNúmero do lote
      MOUSE ANTI-DENGUE TYPE 2 VIRUS MONOCLONAL ANTIBODY - 2147059 2147059
      MOUSE ANTI-DENGUE TYPE 2 VIRUS MONOCLONAL ANTIBODY - 2430510 2430510
      MOUSE ANTI-DENGUE TYPE 2 VIRUS - 2090453 2090453
      MOUSE ANTI-DENGUE TYPE 2 VIRUS -2521469 2521469
      MOUSE ANTI-DENGUE TYPE 2 VIRUS -2621038 2621038
      MOUSE ANTI-DENGUE TYPE 2 VIRUS -2691365 2691365
      MOUSE ANTI-DENGUE TYPE 2 VIRUS -2739113 2739113
      MOUSE ANTI-DENGUE TYPE 2 VIRUS -2762356 2762356
      MOUSE ANTI-DENGUE TYPE 2 VIRUS -2786063 2786063
      MOUSE ANTI-DENGUE TYPE 2 VIRUS MONOCLONAL ANTIBODY - 2015555 2015555
      MOUSE ANTI-DENGUE TYPE 2 VIRUS MONOCLONAL ANTIBODY - 2049800 2049800
      MOUSE ANTI-DENGUE TYPE 2 VIRUS MONOCLONAL ANTIBODY - 2207176 2207176
      MOUSE ANTI-DENGUE TYPE 2 VIRUS MONOCLONAL ANTIBODY - 2359953 2359953

      Referências

      Visão geral das referênciasPub Med ID
      Dengue virus induces and requires glycolysis for optimal replication.
      Fontaine, KA; Sanchez, EL; Camarda, R; Lagunoff, M
      Journal of virology 89 2358-66 2015

      Mostrar Resumo
      25505078 25505078
      Sialic acid expression in the mosquito Aedes aegypti and its possible role in dengue virus-vector interactions.
      Cime-Castillo, J; Delannoy, P; Mendoza-Hernández, G; Monroy-Martínez, V; Harduin-Lepers, A; Lanz-Mendoza, H; Hernández-Hernández, Fde L; Zenteno, E; Cabello-Gutiérrez, C; Ruiz-Ordaz, BH
      BioMed research international 2015 504187 2015

      Mostrar Resumo
      25874215 25874215
      Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly.
      de Wispelaere, M; Yang, PL
      Journal of virology 86 7072-83 2012

      Mostrar Resumo
      22532681 22532681
      An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro.
      De Burghgraeve, T; Kaptein, SJ; Ayala-Nunez, NV; Mondotte, JA; Pastorino, B; Printsevskaya, SS; de Lamballerie, X; Jacobs, M; Preobrazhenskaya, M; Gamarnik, AV; Smit, JM; Neyts, J
      PloS one 7 e37244 2012

      Mostrar Resumo
      22624001 22624001
      Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells.
      van der Schaar, HM; Rust, MJ; Chen, C; van der Ende-Metselaar, H; Wilschut, J; Zhuang, X; Smit, JM
      PLoS pathogens 4 e1000244 2008

      Mostrar Resumo Texto completo do artigo
      19096510 19096510
      Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking.
      van der Schaar, HM; Rust, MJ; Waarts, BL; van der Ende-Metselaar, H; Kuhn, RJ; Wilschut, J; Zhuang, X; Smit, JM
      Journal of virology 81 12019-28 2007

      Mostrar Resumo Texto completo do artigo
      17728239 17728239
      Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies.
      Gentry, M K, et al.
      Am. J. Trop. Med. Hyg., 31: 548-55 (1982) 1982

      Mostrar Resumo
      6177259 6177259
      Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence
      Henchal, E A, et al
      Am J Trop Med Hyg, 31:830-6 (1982) 1982

      6285749 6285749

      Ficha de dados

      Título
      MOUSE ANTI-DENGUE TYPE 2 VIRUS MONOCLONAL ANTIBODY